EFPIA Touts Innovative Medicines Model In China
This article was originally published in PharmAsia News
Executive Summary
China is aiming to increase investment in R&D and education as new economic growth platforms, with new drug research including translational medicine seen as a key component. Sanofi CEO Chris Viehbacher has made his views heard on the issue in his role as chairman of the European Federation for Pharmaceutical Industries and Associations (EFPIA), which made its first official visit to China last month.